Related Experiment Video
Updated: Jun 8, 2026

Animal Models of Depression - Chronic Despair Model (CDM)
Published on: September 23, 2021
Evidence for GABAergic inhibitory deficits in major depressive disorder
Paul E Croarkin1, Andrea J Levinson, Zafiris J Daskalakis
1Department of Psychiatry, UT Southwestern Medical Center Dallas, 6300 Harry Hines Boulevard, Suite 1200, Dallas, TX 75390-8589, USA. paul.croarkin@utsouthwestern.edu
Abstract:
Converging evidence suggests that deficits in gamma-aminobutyric acid (GABA) functioning are implicated in the pathophysiology of major depressive disorder (MDD). This is highlighted by research investigating cortical inhibition (CI), a process whereby GABAergic interneurons selectively attenuate pyramidal neurons. Transcranial magnetic stimulation (TMS) paradigms evaluate this marker of neuronal inhibitory activity in the cortex. This review will examine the neuroanatomic and neurophysiological evidence from neuroimaging, molecular, treatment, and TMS studies linking dysfunctional GABAergic neurotransmission to MDD.
Related Concept Videos
Depressive Disorders: Etiology
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
Depressive Disorders: MDD and Dysthymia
Depression: Overview
G-protein Coupled Receptors
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antidepressant Drugs: MAOIs and Other Agents

